Upacicalcet: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A calcimimetic | {{Short description|A calcimimetic agent used in the treatment of secondary hyperparathyroidism}} | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | |||
| verifiedrevid = 123456789 | | verifiedrevid = 123456789 | ||
| image = Upacicalcet.svg | | image = Upacicalcet.svg | ||
| | | image_size = 200px | ||
| | | image_alt = Structural formula of Upacicalcet | ||
}} | }} | ||
'''Upacicalcet''' is a [[calcimimetic]] | '''Upacicalcet''' is a [[calcimimetic]] agent used primarily in the management of [[secondary hyperparathyroidism]] in patients with [[chronic kidney disease]] (CKD) undergoing [[dialysis]]. It functions by modulating the activity of the [[calcium-sensing receptor]] (CaSR) on the [[parathyroid gland]], thereby reducing the secretion of [[parathyroid hormone]] (PTH). | ||
==Mechanism of | ==Mechanism of action== | ||
Upacicalcet | Upacicalcet acts as an allosteric modulator of the calcium-sensing receptor, which is a G-protein coupled receptor located on the surface of the parathyroid cells. By enhancing the sensitivity of the CaSR to extracellular calcium, upacicalcet effectively lowers PTH levels, which in turn helps to manage the mineral and bone disorder associated with CKD. | ||
==Clinical | ==Clinical use== | ||
Upacicalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. It is administered intravenously, typically during dialysis sessions | Upacicalcet is indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis. It is administered intravenously, typically during dialysis sessions, to ensure optimal control of PTH levels. | ||
==Side | ==Side effects== | ||
Common side effects of upacicalcet include [[nausea]], [[vomiting]], and [[hypocalcemia]]. | Common side effects of upacicalcet include [[nausea]], [[vomiting]], and [[hypocalcemia]]. Patients receiving upacicalcet should be monitored for signs of low calcium levels, as severe hypocalcemia can lead to [[muscle cramps]], [[seizures]], and [[cardiac arrhythmias]]. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
Upacicalcet is administered intravenously, allowing for | Upacicalcet is administered intravenously, allowing for rapid onset of action. It is metabolized primarily in the liver and excreted via the kidneys. The pharmacokinetic profile of upacicalcet supports its use in patients undergoing dialysis, as it is not significantly removed by the dialysis process. | ||
==Related pages== | |||
==Related | |||
* [[Calcimimetic]] | * [[Calcimimetic]] | ||
* [[Secondary hyperparathyroidism]] | * [[Secondary hyperparathyroidism]] | ||
* [[Chronic kidney disease]] | * [[Chronic kidney disease]] | ||
* [[Dialysis]] | * [[Dialysis]] | ||
* [[Parathyroid hormone]] | |||
[[Category:Calcimimetics]] | [[Category:Calcimimetics]] | ||
[[Category:Drugs used in nephrology]] | [[Category:Drugs used in nephrology]] | ||
Revision as of 03:40, 13 February 2025
A calcimimetic agent used in the treatment of secondary hyperparathyroidism
| Upacicalcet | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Upacicalcet is a calcimimetic agent used primarily in the management of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) undergoing dialysis. It functions by modulating the activity of the calcium-sensing receptor (CaSR) on the parathyroid gland, thereby reducing the secretion of parathyroid hormone (PTH).
Mechanism of action
Upacicalcet acts as an allosteric modulator of the calcium-sensing receptor, which is a G-protein coupled receptor located on the surface of the parathyroid cells. By enhancing the sensitivity of the CaSR to extracellular calcium, upacicalcet effectively lowers PTH levels, which in turn helps to manage the mineral and bone disorder associated with CKD.
Clinical use
Upacicalcet is indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis. It is administered intravenously, typically during dialysis sessions, to ensure optimal control of PTH levels.
Side effects
Common side effects of upacicalcet include nausea, vomiting, and hypocalcemia. Patients receiving upacicalcet should be monitored for signs of low calcium levels, as severe hypocalcemia can lead to muscle cramps, seizures, and cardiac arrhythmias.
Pharmacokinetics
Upacicalcet is administered intravenously, allowing for rapid onset of action. It is metabolized primarily in the liver and excreted via the kidneys. The pharmacokinetic profile of upacicalcet supports its use in patients undergoing dialysis, as it is not significantly removed by the dialysis process.
